BR0111473A - Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológica - Google Patents
Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológicaInfo
- Publication number
- BR0111473A BR0111473A BR0111473-5A BR0111473A BR0111473A BR 0111473 A BR0111473 A BR 0111473A BR 0111473 A BR0111473 A BR 0111473A BR 0111473 A BR0111473 A BR 0111473A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- disease
- screening
- methods
- pomp
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"MéTODOS PARA TRIAR UM INDIVìDUO QUANTO A UMA DOENçA DE ARMAZENAGEM DE GLICOGêNIO, PARA TRIAR UM INDIVìDUO QUANTO à DOENçA DE POMPE, PARA MONITORAR A CONDIçãO CLìNICA DE UM INDIVìDUO COM DOENçA DE POMPE, PARA ESTIMAR A EFICáCIA DE UM REGIME TERAPêUTICO EM UM INDIVìDUO COM DOENçA DE POMPE E PARA DETERMINAR A CONCENTRAçãO DE UM OLIGOSSACARìDEO EM UMA AMOSTRA BIOLóGICA". São providos métodos de triar indivíduos quanto a doenças de armazenagem lisossomal, preferivelmente doenças de armazenagem de glicogênio, empregando-se um tetrassacarídeo como um biomarcador. Em uma versão mais preferida, os indivíduos são triados quanto à doença de Pompe (isto é, doença de armazenagem de glicogênio tipo II). São também providos ensaios de triagem neonatal. A presente invenção provê ainda métodos de monitoração da condição clínica e eficácia do tratamento terapêutico em indivíduos afetados. São ainda providos métodos de medir um biomarcador de tetrassacarídeo por espectrometria de massa seq³encial, preferivelmente como parte de um ensaio de triagem neonatal para a doença de Pompe.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20992000P | 2000-06-07 | 2000-06-07 | |
PCT/US2001/018288 WO2001094941A2 (en) | 2000-06-07 | 2001-06-06 | Diagnostic methods for pompe disease and other glycogen storage diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0111473A true BR0111473A (pt) | 2004-01-13 |
Family
ID=22780875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111473-5A BR0111473A (pt) | 2000-06-07 | 2001-06-06 | Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológica |
Country Status (9)
Country | Link |
---|---|
US (1) | US20020102737A1 (pt) |
EP (1) | EP1360485A2 (pt) |
JP (1) | JP2004501365A (pt) |
KR (1) | KR20030021167A (pt) |
AU (1) | AU2001266733A1 (pt) |
BR (1) | BR0111473A (pt) |
CA (1) | CA2409989A1 (pt) |
MX (1) | MXPA02012032A (pt) |
WO (1) | WO2001094941A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7196323B2 (en) * | 2002-02-28 | 2007-03-27 | Metanomics Gmbh & Co. Kgaa | Mass spectrometry method for analyzing mixtures of substances |
AU2003220321A1 (en) * | 2002-03-15 | 2003-09-29 | University Of Utah | Methods for quantitative analysis by tandem mass spectrometry |
EP1497650A4 (en) * | 2002-04-30 | 2008-04-02 | Seikagaku Kogyo Co Ltd | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES |
US6800489B2 (en) * | 2002-06-05 | 2004-10-05 | Izaak Walton Killam Health Center | Electrospray tandem mass spectrometry of transition metal diimine complexes of amino acids, α-hydroxyketones and hexose phosphates for newborn screening |
AUPS293002A0 (en) * | 2002-06-14 | 2002-07-04 | Women's And Children's Hospital | Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders |
US20040096896A1 (en) * | 2002-11-14 | 2004-05-20 | Cedars-Sinai Medical Center | Pattern recognition of serum proteins for the diagnosis or treatment of physiologic conditions |
US7129049B2 (en) * | 2003-12-22 | 2006-10-31 | Regents Of The University Of Minnesota | Method of detecting equine glycogen storage disease IV |
ES2356343T3 (es) * | 2005-05-20 | 2011-04-07 | Germediq Forschungs- Und Entwicklungsgesellschaft Mbh | Método para la determinación de factores de riesgo cardiovasculares en sangre desecada. |
US8093062B2 (en) * | 2007-03-22 | 2012-01-10 | Theodore Winger | Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil |
US8202686B2 (en) * | 2007-03-22 | 2012-06-19 | Advanced Liquid Logic, Inc. | Enzyme assays for a droplet actuator |
US8440392B2 (en) * | 2007-03-22 | 2013-05-14 | Advanced Liquid Logic Inc. | Method of conducting a droplet based enzymatic assay |
US8497122B2 (en) * | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
US8232073B2 (en) | 2009-01-02 | 2012-07-31 | Zacharon Pharmaceuticals, Inc. | Quantification of non-reducing end glycan residual compounds |
US9029530B2 (en) | 2009-01-02 | 2015-05-12 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
US8809009B2 (en) | 2009-01-02 | 2014-08-19 | Biomarin Pharmaceutical Inc. | Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker |
US8592140B2 (en) | 2009-01-02 | 2013-11-26 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
EP2516669B1 (en) | 2009-12-21 | 2016-10-12 | Advanced Liquid Logic, Inc. | Enzyme assays on a droplet actuator |
US9513253B2 (en) | 2011-07-11 | 2016-12-06 | Advanced Liquid Logic, Inc. | Droplet actuators and techniques for droplet-based enzymatic assays |
US9575064B2 (en) * | 2014-09-02 | 2017-02-21 | Perkinelmer Health Sciences, Inc. | Methods relating to testing for lysosomal storage disorders |
JP2021036232A (ja) | 2019-08-23 | 2021-03-04 | Jcrファーマ株式会社 | 脳脊髄液に含まれるHex4,lyso−GM1,Fuc−GlcNAc−Asn,及びlyso−sulfatideの定量法 |
CN111610275A (zh) * | 2020-06-08 | 2020-09-01 | 山东省分析测试中心 | 一种低聚麦芽糖的测定方法及在产品质量控制领域的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252489A (en) * | 1989-01-17 | 1993-10-12 | Macri James N | Down syndrome screening method utilizing dried blood samples |
-
2001
- 2001-06-06 WO PCT/US2001/018288 patent/WO2001094941A2/en not_active Application Discontinuation
- 2001-06-06 CA CA002409989A patent/CA2409989A1/en not_active Abandoned
- 2001-06-06 BR BR0111473-5A patent/BR0111473A/pt not_active Application Discontinuation
- 2001-06-06 MX MXPA02012032A patent/MXPA02012032A/es unknown
- 2001-06-06 EP EP01944308A patent/EP1360485A2/en not_active Withdrawn
- 2001-06-06 AU AU2001266733A patent/AU2001266733A1/en not_active Abandoned
- 2001-06-06 KR KR1020027016474A patent/KR20030021167A/ko not_active Application Discontinuation
- 2001-06-06 US US09/875,327 patent/US20020102737A1/en not_active Abandoned
- 2001-06-06 JP JP2002502439A patent/JP2004501365A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2409989A1 (en) | 2001-12-13 |
JP2004501365A (ja) | 2004-01-15 |
KR20030021167A (ko) | 2003-03-12 |
EP1360485A2 (en) | 2003-11-12 |
AU2001266733A1 (en) | 2001-12-17 |
WO2001094941A3 (en) | 2003-08-21 |
US20020102737A1 (en) | 2002-08-01 |
MXPA02012032A (es) | 2003-04-25 |
WO2001094941A2 (en) | 2001-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0111473A (pt) | Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológica | |
Gram et al. | Skeletal muscle mitochondrial H2O2 emission increases with immobilization and decreases after aerobic training in young and older men | |
Muscettola et al. | Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders: A replication and new findings | |
Durward et al. | All-cause mortality risk of metabolically healthy obese individuals in NHANES III | |
Mitchell et al. | Amyotrophic lateral sclerosis | |
Favier et al. | Downregulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia | |
Shen et al. | Inosine reduces ischemic brain injury in rats | |
Hill et al. | Bioenergetics and translational metabolism: implications for genetics, physiology and precision medicine | |
WO2007006858A3 (en) | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same | |
WO2004047770A3 (en) | Cytotherapeutics, cytotherapeutic units and methods for treatments using them | |
WO2001040517A3 (en) | Evaluating and predicting clinical outcomes by gene expression analysis | |
WO2006073682A3 (en) | Diagnostic test | |
WO2005046570A3 (en) | Human stem cell materials and methods | |
WO2007016532A3 (en) | Mutations and polymorphisms of hdac4 | |
Soyupek et al. | Androgen deprivation therapy for prostate cancer: effects on hand function | |
Smith et al. | Roadmap for advancing pre-clinical science in traumatic brain injury | |
Petry | Gambling disorder: The first officially recognized behavioral addiction. | |
Gwag et al. | Stress and signaling responses of rat skeletal muscle to brief endurance exercise during hindlimb unloading: a catch-up process for atrophied muscle | |
AU2006228990A8 (en) | A method of diagnosis and treatment and agents useful for same | |
Raymond‐Pope et al. | Restricted physical activity after volumetric muscle loss alters whole‐body and local muscle metabolism | |
Wasan et al. | Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients | |
Jachova et al. | Neuroprotection mediated by remote preconditioning is associated with a decrease in systemic oxidative stress and changes in brain and blood glutamate concentration | |
Morimoto et al. | Subclinical decrease in cardiac autonomic and diastolic function in patients with metabolic disorders: HSCAA study | |
Nabrdalik et al. | Diabetic peripheral neuropathy is associated with diabetic kidney disease and cardiovascular disease–The Silesia Diabetes-Heart Project | |
WO2000066782A3 (en) | Diagnostic assay for diabetes mellitus based on mutational burden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |